Press release: invIOs to present at upcoming conferences
Unlocking the master checkpoint of cancer immunity
Our knowledge of cancer is growing daily, bringing with it new treatment strategies. As mentioned previously (here) novel immunotherapies are at the forefront of cancer research. The immune activating monoclonal…
Three questions to Romana Gugenberger, Chief Medical and Scientific Officer
1. Despite novel immune-therapies against cancer there are still non-responders and relapses. Why is that? Romana Gugenberger: Tumors are heterogeneous. Additionally, tumors are not static but evolve. Once a response…
Press release: invIOs goes live
invIOs goes live with unique cell therapy platform and clinical-stage immuno-oncology pipeline Vienna, Austria, 16 December 2021: invIOs (innovative Immuno-Oncology) GmbH, a privately held biotechnology company developing novel therapies for…
The immune system’s fight against cancer
Cancer is the second leading cause of death worldwide. Obviously, the complex cancer biology and simultaneous failure of our body to halt the transformation of a normal cell into cancer…
Perspectives: The Cancer Revolution
Despite recent advances in the treatment of cancer, the disease remains a leading cause of death by disease worldwide1. It is reported that one in two people will be diagnosed…
Press release: APEIRON Biologics launches next clinical trial with innovative cancer therapy APN401
Important development step for promising cell therapy Paradigm shift in cancer treatment: process developed by APEIRON uses immune system to treat solid tumors Innovative new manufacturing and treatment process enables…
Press release: APEIRON Biologics announces changes to management and supervisory boards
Management Board to be expanded by Romana Gugenberger, PhD, as Chief Medical & Scientific Officer (CMSO) and Andreas Gerber, PhD, as Chief Operating Officer (COO) Prof. Josef Penninger moves from…
